Yasuma Yoshizumi, Hiroshi Yukawa, Ryoji Iwaki, Sanae Fujinaka, Ayano Kanou, Yuki Kanou, Tatsuya Yamada, Shingo Nakagawa, Tomomi Ohara, Kenta Nakagiri, Yusuke Ogihara, Yoko Tsutsui, Yumi Hayashi, Masatoshi Ishigami, Yoshinobu Baba, Tetsuya Ishikawa
Cell therapy with adipose tissue-derived stem cells (ASCs) is expected to be a candidate for the treatment of fulminant hepatic failure (FHF), which is caused by excessive immune responses. In order to evaluate the therapeutic effects of ASCs on FHF, the in vitro and in vivo immunomodulatory effects of ASCs were examined in detail in the mouse model. The in vitro effects of ASCs were examined by assessing their influence on the proliferation of lymphomononuclear cells (LMCs) stimulated with three kinds of mitogens: phorbol 12-myristate 13-acetate (PMA) plus ionomycin, concanavalin A (ConA), and lipopolysaccharide (LPS)...
January 8, 2017: Cell Medicine